BC ARTHRITIS STRENGTH

Compare BC ARTHRITIS STRENGTH  to:
Compare
Compare

Generic Name for BC ARTHRITIS STRENGTH

Aspirin 742mg, caffeine 38mg, salicylamide 222mg; per powder; contains potassium 65mg/powder.

Legal Classification:

OTC

Pharmacological Class for BC ARTHRITIS STRENGTH

Salicylate.

Manufacturer of BC ARTHRITIS STRENGTH

GlaxoSmithKline Pharmaceuticals

Indications for BC ARTHRITIS STRENGTH

Minor arthritis pain.

Adult dose for BC ARTHRITIS STRENGTH

Place powder on tongue and follow with liquid; or may stir into glass of water or other liquids. 1 powder every 3–4 hours; max: 4 powders/24 hours.

Children's dosing for BC ARTHRITIS STRENGTH

Not recommended.

Contraindications for BC ARTHRITIS STRENGTH

NSAID allergy. Viral infection in children and teenagers. 3rd trimester pregnancy.

Precautions for BC ARTHRITIS STRENGTH

History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy. Nursing mothers: not recommended.

Interactions for BC ARTHRITIS STRENGTH

Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. Additive effects with other caffeine-containing products.

Adverse Reactions for BC ARTHRITIS STRENGTH

GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism.

How is BC ARTHRITIS STRENGTH supplied?

Powder—6, 24, 50

Related Disease:

Arthritis~NSAIDs

Related Resources

Xiaflex available for Dupuytren's contracture

March 08, 2010

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Xiaflex approved for Dupuytren's contracture

February 03, 2010

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of SBI-087 for treatment of rheumatoid arthritis (RA)

January 11, 2010

Trubion Pharmaceuticals announced the initiation of a Phase 2 trial of SBI-087 for the treatment of rheumatoid arthritis (RA).

Actemra approved for moderately to severely active rheumatoid arthritis

January 11, 2010

The FDA has approved Actemra (tocilizumab, from Roche) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.